Top news of May: Implications of high HDL, celebrating 20 years of TAVR and more

Healio and Cardiology Today have compiled a list of the most-read news in cardiology of May 2022.

Readers were most interested in very high HDL as an indicator of mortality in those with CAD; an Apple watch app to detect left ventricular dysfunction; the topline results of the DELIVER trial; and more.

Very high HDL ‘red flag’ for all-cause, CV death risk in adults with CAD

In adults with CAD, those with HDL of 80 mg/dL or greater are nearly twice as likely to die of any cause compared with those with HDL between 40 mg/dL and 60 mg/dL, according to an analysis of two large biobank databases. Read more

Apple Watch app, using AI, identifies left ventricular dysfunction

Applying artificial intelligence to an Apple Watch ECG can reliably and safely identify left ventricular dysfunction in a nonclinical setting, researchers reported in a proof-of-concept study. Read more

Mediterranean diet better than low-fat plan for secondary CV prevention: CORDIOPREV

A Mediterranean diet was superior to a low-fat diet in preventing major CV events in secondary prevention of CVD, according to findings from the CORDIOPREV study. Read more

Time-restricted eating may reduce CV risk for older breast cancer survivors

Older women with overweight who received cardiotoxic treatment for breast cancer saw a 15% relative CVD risk reduction after following an 8-week time-restricted eating plan, according to research published in JACC: CardioOncology. Read more

DELIVER topline results: Dapagliflozin reduces CV death, worsening HF in EF more than 40%

Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults with HF with mildly reduced or preserved ejection fraction, AstraZeneca announced. Read more

From ‘disruptive technology’ to standard of care: Celebrating 20 years of TAVR

This year marks 2 decades since the first transcatheter aortic valve replacement procedure was performed on an inoperable patient with severe symptomatic aortic stenosis — a historic moment that would change interventional cardiology. Read more

Fast-acting nasal spray safe for self-treatment of paroxysmal supraventricular tachycardia

A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal supraventricular tachycardia during long-term follow-up, according to findings from the open-label NODE-302 study. Read more

AHA: Investments, improvements in research critical for equity in women’s heart health

Clinicians and researchers must address pervasive gaps in knowledge and care delivery to reduce sex-based disparities and achieve equity in cardiology care, according to a presidential advisory from the American Heart Association. Read more

mRNA technology may have potential to repair, regenerate cardiac tissue

Tissue regeneration has been achieved in certain parts of the body, but not the heart. That could change if a novel therapeutic derived from messenger RNA succeeds. Read more

Long-term clopidogrel confers less MACCE, bleeding events vs. aspirin after PCI

ATLANTA — Clopidogrel monotherapy after 12 months of event free post-PCI dual antiplatelet therapy was associated with fewer MACCE and bleeding events vs. aspirin monotherapy in patients at high bleeding risk, a speaker reported. Read more